PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 1, 2026Brain and Development Case ReportsOpen Access

Methyldopa as a novel therapeutic option for paroxysmal sympathetic hyperactivity in pediatric patients: A case report

View Full Paper
Ask AI
Bookmark
Share

Authors

MUMika UkaiHTHiroshi TerashimaKHKoji Hirohata

Discussion

Loading...

Member takes

Overview

Case report shows methyldopa alleviates symptoms of paroxysmal sympathetic hyperactivity in children, suggesting it as a viable treatment option.

Key Points

  • To explore methyldopa as a potential treatment for paroxysmal sympathetic hyperactivity (PSH) in pediatric patients.
  • Documented two pediatric cases of PSH managed with methyldopa.
  • Monitored symptoms and treatment outcomes for both cases.
  • Compared the efficacy of methyldopa to previous treatment with clonidine.
  • Case 1 showed successful management of PSH symptoms after switching from clonidine to methyldopa.
  • Case 2 experienced alleviation of PSH symptoms and lower creatine kinase levels after treatment with methyldopa and gabapentin.
  • Both cases suggest methyldopa can be a suitable alternative where clonidine is unavailable.

Cite This Study

Ukai et al. (2026) studied this question.

synapsesocial.com/papers/69cd79e15652765b073a6b1chttps://doi.org/10.1016/j.bdcasr.2026.100140
View Full Paper
Ask AI
Bookmark
Share